Valuation dashboard for Boundless Bio, Inc. (BOLD) with P/E N/A, P/B 0.96, EV/EBITDA -0.76 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $2.82, BOLD has negative trailing earnings (P/E not meaningful) and an ROE of -70.89%. Market capitalisation stands at $63M.
Balance sheet quality for BOLD: current ratio of 8.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-1.46 |
| vs Current Price | -151.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BOLD | Boundless Bio, Inc. | $63M | 0.96 | -70.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.82 |
| Market Cap | $63M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -70.89% |
| Return on Invested Capital | -103.08% |
| Return on Assets | -86.80% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · INTS · ITRM · NXTC · PLUR · PSTV · QTTB
Explore sector: Healthcare · Biotechnology
More sections of BOLD: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks